Roy M. Gulick

20.9k total citations · 3 hit papers
168 papers, 10.6k citations indexed

About

Roy M. Gulick is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Roy M. Gulick has authored 168 papers receiving a total of 10.6k indexed citations (citations by other indexed papers that have themselves been cited), including 151 papers in Infectious Diseases, 128 papers in Virology and 24 papers in Emergency Medicine. Recurrent topics in Roy M. Gulick's work include HIV/AIDS drug development and treatment (131 papers), HIV Research and Treatment (128 papers) and HIV/AIDS Research and Interventions (104 papers). Roy M. Gulick is often cited by papers focused on HIV/AIDS drug development and treatment (131 papers), HIV Research and Treatment (128 papers) and HIV/AIDS Research and Interventions (104 papers). Roy M. Gulick collaborates with scholars based in United States, United Kingdom and Spain. Roy M. Gulick's co-authors include Fernando J. Martínez, David Berlin, Heather J. Ribaudo, Joseph J. Eron, Edward P. Acosta, Daniel R. Kuritzkes, John W. Mellors, Diane V. Havlir, Douglas D. Richman and Anne R. Meibohm and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Investigation.

In The Last Decade

Roy M. Gulick

166 papers receiving 10.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy

1997 1.5k citations Roy M. Gulick, John W. Mellors et al. New England Journal of Medicine profile →
Severe Covid-19

2020 928 citations Roy M. Gulick et al. New England Journal of Medicine profile →
Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

2008 570 citations Roy M. Gulick, Jacob Lalezari et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Roy M. Gulick

Since Specialization

Citations

This map shows the geographic impact of Roy M. Gulick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roy M. Gulick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roy M. Gulick more than expected).

Fields of papers citing papers by Roy M. Gulick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roy M. Gulick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roy M. Gulick. The network helps show where Roy M. Gulick may publish in the future.

Co-authorship network of co-authors of Roy M. Gulick

This figure shows the co-authorship network connecting the top 25 collaborators of Roy M. Gulick. A scholar is included among the top collaborators of Roy M. Gulick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roy M. Gulick. Roy M. Gulick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305 2021 ·Journal of Antimicrobial Chemotherapy ·Todd T. Brown, Krista Yuhas, Kenneth H. Mayer, Raphael J. Landovitz, Mark A. Marzinke, Craig W. Hendrix, Ying Qing Chen, (unknown), Wairimu Chege, Marybeth McCauley, Roy M. Gulick, Timothy Wilkin	4
2	Selecting Treatments During an Infectious Disease Pandemic: Chasing the Evidence 2021 ·Annals of Internal Medicine ·Marshall J. Glesby, Roy M. Gulick	3
3	Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19 2021 ·Annals of Internal Medicine ·Safia Kuriakose, (unknown), Alice K. Pau, Eric S. Daar, Rajesh T. Gandhi, Pablo Tebas, Laura Evans, Roy M. Gulick, H. Clifford Lane, Henry Masur	13
4	Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection 2021 ·Journal of Biomolecular Structure and Dynamics ·Dennis C. Copertino, (unknown), Rodrigo R. R. Duarte, Timothy R. Powell, Christopher E. Ormsby, Timothy Wilkin, Roy M. Gulick, Miguel de Mulder Rougvie, Douglas F. Nixon	13
5	Blood component utilization in COVID‐19 patients in New York City: Transfusions do not follow the curve 2020 ·Transfusion ·Robert A. DeSimone, (unknown), Kathleen Kane, Jorge L. Sepulveda, Grant Ellsworth, Roy M. Gulick, Jason Zucker, (unknown), Joseph E. Schwartz, Melissa M. Cushing	14
6	Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells 2018 ·AIDS Research and Human Retroviruses ·(unknown), (unknown), Joseph Tillotson, Paul Richardson, Leslie Cottle, Marybeth McCauley, Raphael J. Landovitz, Adriana Andrade, Craig W. Hendrix, Kenneth H. Mayer, Timothy Wilkin, Roy M. Gulick, Namandjé N. Bumpus	13
7	Choosing Initial Antiretroviral Therapy: Current Recommendations for Initial Therapy and Newer or Investigational Agents. 2016 ·PubMed ·Roy M. Gulick	3
8	Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City 2015 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Matthew S. Simon, Don Weiss, Anita Geevarughese, (unknown), Blayne Cutler, Roy M. Gulick, Jane R. Zucker, Jay K. Varma, Bruce R. Schackman	9
9	Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients 2013 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Roy M. Gulick, Gerd Fätkenheuer, (unknown), William D. Hardy, Mark Nelson, James Goodrich, Geoffrey Mukwaya, Simon Portsmouth, Jayvant Heera	31
10	Seven-Year Efficacy of a Lopinavir/Ritonavir-Based Regimen in Antiretroviral—Naïve HIV-1-Infected Patients 2008 ·HIV Clinical Trials ·Robert L. Murphy, Barbara A. da Silva, Charles B. Hicks, Joseph J. Eron, Roy M. Gulick, Melanie Thompson, (unknown), Martin King, George J. Hanna, Scott C. Brun	52
11	Maraviroc for Previously Treated Patients with R5 HIV-1 Infection breakdown → 2008 ·New England Journal of Medicine ·Roy M. Gulick, Jacob Lalezari, James Goodrich, Nathan Clumeck, Edwin DeJesus, Andrzej Horban, Jeffrey P. Nadler, Bonaventura Clotet, Anders Karlsson, Michael Wohlfeiler, (unknown), (unknown), John F. Sullivan, Caroline E. Ridgway, Steve Felstead, Michael W. Dunne, Elna van der Ryst, Howard Mayer	570
12	Metabolic Effects of Protease Inhibitor-Sparing Antiretroviral Regimens Given as Initial Treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095) 2007 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Cecilia M. Shikuma, (unknown), Marshall J. Glesby, William A. Meyer, Karen T. Tashima, Heather J. Ribaudo, Nancy R. Webb, Barbara Bastow, Daniel R. Kuritzkes, Roy M. Gulick	42
13	Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV‐1–Infected, Treatment‐Experienced Patients: AIDS Clinical Trials Group 5211 2007 ·The Journal of Infectious Diseases ·Roy M. Gulick, Zhaohui Su, Charles Flexner, Michael D. Hughes, Paul R. Skolnik, Timothy Wilkin, Robert Gross, Amy Krambrink, Eoin Coakley, Wayne Greaves, Andrew Zolopa, Richard C. Reichman, Catherine Godfrey, Martin Hirsch, Daniel R. Kuritzkes	195
14	Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study 2006 ·Clinical Infectious Diseases ·Heather J. Ribaudo, David W. Haas, C. Tierney, Richard B. Kim, G. Wilkinson, Roy M. Gulick, David B. Clifford, Catia Marzolini, Courtney V. Fletcher, Karen T. Tashima, Daniel R. Kuritzkes, Edward P. Acosta	170
15	A Randomized Trial of Treatment Interruption before Optimized Antiretroviral Therapy for Persons with Drug‐Resistant HIV: 48‐Week Virologic Results of ACTG A5086 2006 ·The Journal of Infectious Diseases ·Constance A. Benson, Florin Vaida, Diane V. Havlir, Gerald Downey, Michael M. Lederman, Roy M. Gulick, Marshall J. Glesby, Michael Wantman, (unknown), Alex R. Rinehart, Sally Snyder, Rui Wang, (unknown), John W. Mellors, (unknown)	18
16	Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection 2004 ·New England Journal of Medicine ·Roy M. Gulick, Heather J. Ribaudo, Cecilia M. Shikuma, Stephanie Lustgarten, Kathleen Squires, William A. Meyer, Edward P. Acosta, Bruce R. Schackman, Christopher D. Pilcher, Robert L. Murphy, William E. Maher, Mallory D. Witt, Richard C. Reichman, Sally Snyder, Karin L. Klingman, Daniel R. Kuritzkes	396
17	Case-Control Study of Diabetes Mellitus in HIV-Infected Patients 2004 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·(unknown), Roy M. Gulick, Donald R. Hoover, Carlos Vaamonde, Marshall J. Glesby	23
18	Efficacy and Treatment-Limiting Toxicity With the Concurrent Use of Lopinavir/Ritonavir and a Third Protease Inhibitor in Treatment-Experienced HIV-Infected Patients 2003 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·(unknown), Marshall J. Glesby, (unknown), Roy M. Gulick	8
19	When to switch and what to switch to: strategic use of antiretroviral therapy. 2000 ·PubMed ·Roy M. Gulick	3
20	The Seventh Conference on Retroviruses and Opportunistic Infections. 2000 ·PubMed ·(unknown), Roy M. Gulick, (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact